Cyclo Therapeutics (CYTH) Stock Price, News & Analysis

Company Overview

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Key Stats

• Today's Range: $0.72 to $0.72
• 50-Day Range: $0.72 to $0.72
• 52-Week Range: $0.55 to $1.45
• Volume: N/A
• Average Volume: 492,760 shs
• Market Capitalization: $23.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.95
• Consensus Rating: Hold

CYTH Stock Analysis - Frequently Asked Questions

How have CYTH shares performed this year?

Cyclo Therapeutics' stock was trading at $0.59 at the beginning of the year. Since then, CYTH stock has increased by 22.1% and is now trading at $0.7206.
View the best growth stocks for 2025 here.

How were Cyclo Therapeutics' earnings last quarter?

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) announced its earnings results on Thursday, August, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07. The firm earned $0.12 million during the quarter, compared to analyst estimates of $0.40 million.

How do I buy shares of Cyclo Therapeutics?

Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cyclo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Video Communications (ZM) and Fisker (FSR).

Company Calendar

• Last Earnings: 8/15/2024
• Today: 6/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CYTH
• CIK: 922247
• Web: www.ctd-holdings.com
• Phone: (386) 418-8060
• Fax: 321-244-8351
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $0.95
• High Stock Price Target: $0.95
• Low Stock Price Target: $0.95
• Potential Upside/Downside: +31.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.06 million
• Net Margins: -2,847.19%
• Pretax Margin: -2,847.30%
• Return on Equity: N/A
• Return on Assets: -307.16%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.17
• Quick Ratio: 0.16

Sales & Book Value

• Annual Sales: $870,725.00
• Price / Sales: 27.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.21 per share
• Price / Book: 3.43

Miscellaneous

• Outstanding Shares: 32,919,000
• Free Float: 23,116,000
• Market Cap: $23.72 million
• Optionable: No Data
• Beta: -0.57